Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.

Authors

Stefan Kubicka

District Clinic Reutlingen, Reutlingen, Germany

Stefan Kubicka , Richard Greil , Thierry André , Jaafar Bennouna , Javier Sastre , Eric Van Cutsem , Roger Von Moos , Pia J. Osterlund , Priti Hegde , Martina A. Sersch , Stuart Osborne , Frank Hermann , Dirk Arnold

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2014 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon and Rectum

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT00700102

Citation

J Clin Oncol 32, 2014 (suppl 3; abstr 520)

DOI

10.1200/jco.2014.32.3_suppl.520

Abstract #

520

Poster Bd #

C25

Abstract Disclosures

FEATURED

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.

Authors

Stefan Kubicka

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.